Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Top Cited Papers
- 8 March 2001
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (10) , 699-709
- https://doi.org/10.1056/nejm200103083441001
Abstract
Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate of death from any cause among patients with severe sepsis.Keywords
This publication has 35 references indexed in Scilit:
- Disseminated Intravascular CoagulationNew England Journal of Medicine, 1999
- AGE-SPECIFIC INCIDENCE AND OUTCOME OF SEPSIS IN THE USCritical Care Medicine, 1999
- Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic ShockSeminars in Thrombosis and Hemostasis, 1998
- The natural history of the systemic inflammatory response syndrome (SIRS). A prospective studyPublished by American Medical Association (AMA) ,1995
- Epidemic Meningococcemia and Purpura Fulminans with Induced Protein C DeficiencyClinical Infectious Diseases, 1993
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992
- Characterization and Novel Purification of Recombinant Human Protein C from Three Mammalian Cell LinesNature Biotechnology, 1990
- From the Centers for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia--United States, 1979-1987Published by American Medical Association (AMA) ,1990
- Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.Journal of Clinical Investigation, 1987
- APACHE IICritical Care Medicine, 1985